Oxford University Press
In 2010, the Infectious Diseases Society of America called for 10 new antibiotics by 2020 . This goal was achieved in terms of the number of drug approvals, but actual patient access requires commercial launches in many countries, which itself requires sustainable commercial markets. Prior work has described limited access to new antibacterials in low- and middle-income countries (LMICs), in part due to the inability of many to afford these drugs . This study examines patient access for new antibacterials in the G7 and 7 other high-income countries in Europe, to better understand other barriers to patient access to effective antibacterial therapy.
Kevin Outterson, Ebiowei S. Orubu, Muhammad H. Zaman, John Rex & Christine Ardal,
Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020
Clinical Infectious Diseases
Available at: https://scholarship.law.bu.edu/faculty_scholarship/1340